Skip to main content
Figure 3 | Vascular Cell

Figure 3

From: Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

Figure 3

MMP-2 ELISA analysis of conditioned media from tsc2ang1 cells treated with either rapamycin, imatinib or the combination for 24 hours resulted in a decrease in the amount of MMP-2 produced in comparison to controls. MMP-2 levels in the tsc2ang1 cells treated with imatinib only and imatinib + rapamycin were significantly decreased compared to that of controls.

Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us